SHINE Technologies, a nuclear fusion company with a platform of medical isotope products, announced it has entered into a definitive agreement to acquire the SPECT business from Lantheus, a leading radiopharmaceutical-focused company. The acquisition will include the portion of the North Billerica, Massachusetts campus that manufactures Lantheus’ SPECT products. SHINE and Lantheus share a commitment to ensuring consistent patient access to critical medical isotopes. By combining SHINE’s fusion-based isotope manufacturing technology with Lantheus’ established market channels, the transaction creates powerful synergies that strengthen SHINE’s leadership in the nuclear medicine market.
Read the full article: SHINE Technologies Announces Plan to Acquire Lantheus’ SPECT Division, Expanding Market Reach and Leadership in Nuclear Medicine //
Source: https://www.prnewswire.com/news-releases/shine-technologies-announces-plan-to-acquire-lantheus-spect-division-expanding-market-reach-and-leadership-in-nuclear-medicine-302445402.html